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Abstract
Background: Genetic alterations of mucin genes, such as MUC2 and MUC4, were previously identified to be
associated with endometriosis and related infertility. Additionally, gene expression profiling has confirmed MUC17
to be overexpressed in mucinous ovarian carcinoma; however, its associated risk for endometriosis remains unclear.
This study was focused on the potential impact of genetic variations in MUC17 on endometriosis development and
associated clinical features.
Methods: The study subjects included 189 female Taiwanese patients with pathology-proven endometriosis and
191 healthy Taiwanese women as controls. Five single-nucleotide polymorphisms (rs4729645, rs10953316,
rs74974199, rs4729655, and rs4729656) within the MUC17 gene were selected and genotyped using the Taqman
genotyping assay to examine the allele frequency and genotype distributions of MUC17 polymorphisms.
Results: Genotyping revealed that the A allele at rs10953316 in MUC17 was a protective genetic factor in endometriosis
development (p = 0.008; OR = 0.53; 95 % CI: 0.36-0.79). Genetic variation of rs4729655 protected patients against
endometriosis-induced infertility, but was associated with a higher cancer antigen 125 (CA125) level. Base-pairing analysis,
called MaxExpect, predicted an additional loop in the mRNA structure caused by rs10953316 polymorphism, possibly
influencing ribosome sliding and translation efficiency. Such predictions were confirmed by immunohistochemistry that
patients with AA genotype at rs10953316 showed low MUC17 levels in their endometrium, patients with GA genotype
showed moderate levels, and strong staining could be found in patients with GG genotype.
Conclusions: MUC17 polymorphisms are involved in endometriosis development and the associated infertility in the
Taiwanese population.
Background
Endometriosis is a common chronic gynecological disease
described as the presence of endometrial glands and
stroma located outside the uterine cavity, ovaries, fallopian
tubes, and even on the bladder or intestines [1, 2]. It occurs
in approximately 10 % of women or teenage girls at re-
productive age. Up to 50 % of patients also suffer from
infertility [3, 4]. Clinical symptoms of endometriosis in-
clude several types of pain, such as excessive menstrual
pain, pelvic pain with defecation, and chronic pelvic pain
[5]. Epidemiological studies revealed a higher risk for endo-
metriosis patients to develop different types of ovarian
cancers [6, 7]. Molecular pathological analyses have pro-
vided strong evidence to support the histological transition
from benign endometriosis to ovarian malignancy [8, 9].
Mucins are high-molecular-weight o-glycoproteins
that function as the protective and lubricative layers on
epithelial surfaces, such as the respiratory, gastrointes-
tinal, and reproductive tracts [10–13]. Gene expression
analyses have indicated that MUC1 ~ 4 are the major
mucins constitutively expressed in endometrial epithe-
lium, and their levels can be controlled by the menstrual
cycle [14, 15]. With potent roles in cellular proliferation,
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MUC1 and MUC4 overexpression has been identified as
a tumor marker for endometriotic lesions and certain
types of ovarian tumors [16, 17]. Interestingly, genetic
polymorphisms in MUC2 and MUC4 were recently re-
ported to be associated with endometriosis development
and the related infertility [18, 19]. Because endometriosis
shares several similarities with cancer (e.g., highly mobile
and proliferative) these data support that alterations in
mucins either at the expression level or within their gen-
etic sequences may have a significant impact on endo-
metrium regulation and development.
In this study, we investigated the association between
genetic variations of MUC17 (A.K.A. MUC3) and endo-
metriosis development based on the finding of gene
expressing profiling in mucinous ovarian carcinoma
(MOC), which likely arises from endometriosis [20, 21].
In this study, the mucin genes MUC2, MUC3A, and
MUC17 were found to be upregulated in MOC [22].
Similar to MUC4, MUC17 encodes a membrane-bound
mucin containing two EGF (epidermal growth factor)-
like domains and a SEA (sea urchin sperm protein, en-
terokinase and agrin) domain in the extracellular por-
tion, which can interact with human EGF receptor 2
(EGFR2) on the adjacent cell surface. Thus, the growth
signal can be transduced to stimulate cellular prolifera-
tion [23]. Of note, MUC17 overexpression can also be
found in colon and pancreatic cancers [24]. Although
several lines of evidence support a potent role of
MUC17 in tumor development, its role in endometriosis
remains unclear. To investigate the possible link with
endometriosis, we studied the association of MUC17
genetic variants with the ovarian cancer biomarker
CA125 and the related infertility.
Methods
Study population
One hundred eighty-nine Taiwanese patients who under-
went surgery for benign ovarian disease and pathology-
proven endometriosis at China Medical University Hos-
pital from 1998 to 2011 were enrolled. These patients
were diagnosed with ovarian cysts by ultrasound and
confirmed by surgical operation. Symptoms of infertility
and CA125 levels were also recorded for each patient
during the study. Patients who failed to have pathology-
proven endometriosis were excluded from this study.
Another 191 healthy women were collected as controls
who had regular health checkups at the same hospital.
Ultrasound assessment indicated healthy conditions in
the abdominal cavities of these controls. Both the con-
trols and patients shared similar age profiles. This study
was approved by the Institutional Review Board of China
Medical University Hospital. Written informed consent
was obtained from patients for scientific research and
publication of this study.
Genotyping
Genomic DNA was extracted from peripheral blood
leukocytes according to the manufacturer’s protocol
(Genomic DNA kit; Qiagen, Valencia, CA, USA). DNA
fragments containing the target single-nucleotide poly-
morphism (SNP) sites were amplified by polymerase
chain reaction (PCR) using the Taqman SNP Genotyping
Assay System from Applied Biosystems, Inc. (Carlsbad,
CA, USA). The probe search and design are available
from the ABI SNP genotyping databank and are listed
in Additional file 1. The PCR amplification conditions
were as follows: 95 °C for 5 minutes, followed by 40 cycles
at 95 °C for 10 seconds, 56 °C for 10 seconds and 72 °C
for 20 seconds, with one additional cycle at 72 °C for 5 mi-
nutes. Genetic variations were detected by reading fluores-
cence signals of the PCR products. A positive signal
indicates a perfect match between the probe and tested
DNA, thus identifying the allele type.
Statistical analysis
The allelic and genotypic frequency distributions for five
SNP sites in endometriosis patients and controls were
performed by χ2 analysis using SPSS software (version
10.0; SPSS Inc. Chicago, IL, USA). Allelic and genotypic
frequencies were expressed as percentages of the total
number of alleles and genotypes. Odds ratios (ORs) were
calculated for the allelic and genotypic frequencies with
95 % confident intervals (95 % CIs). The major (wild-
type) allele was used as the reference group. Lewontin's
D' (|D'|) and the linkage disequilibrium (LD) coefficient
r2 were determined between selected pairs of biallelic
loci. Haploview version 3.2 software (Broad Institute,
Cambridge, MA) was used to examine the structure of
the LD block.
Prediction of mRNA secondary structures adjacent to the
SNP sites
The sequence of rs10953316, as well as the reference se-
quence, were submitted to the RNAstructure web server
(http://rna.urmc.rochester.edu/RNAstructureWeb/index.
html) [25], and structures with maximum expected ac-
curacy were selected. Among the multiple algorithms in
the RNAstructure web server, MaxExpect was utilized to
generate structures composed of highly probable base
pairs with the highest probability of being accurate.
Immunohistochemistry
A total of 76 ectopic endometrial tissues were collected
from patients with different genotypes at the rs10953316
SNP site. Rabbit anti-MUC17 polyclonal antibody
(ab122184) was purchased from Abcam PLC., Cambridge,
USA. Immunohistochemistry was performed with an
antibody dilution of 1:50 using standard protocols with
an EnVision + System peroxidase kit (DAKO Agilent
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Technologies, Glostrup, Denmark). Immunointensity of
MUC17 in endometrial epithelium was independently
scored by two pathologists and specific membrane
staining was labeled as: weak positive, moderately posi-
tive, or strongly positive. For discordant cases, a third
investigator was brought in to score and the final inten-
sity score was determined by the majority scores.
Results
MUC17 polymorphisms and endometriosis
To examine whether SNPs in MUC17 play a role in
endometriosis, five SNPs were selected for this study,
with a frequency greater than 5 % in the Chinese Han in
Beijing from the International HapMap Project databank.
The SNPs locations in MUC17 are indicated in Fig. 1a.
These SNPs were either located in the open reading frame
region or the 3′-untranslated region (3′-UTR) of MUC17.
The LD values of selected SNPs in patients are shown in
Fig. 1B. Genotype analysis and allele distributions of SNPs
in MUC17 in the patients and controls are analyzed in
Table 1. The major (wild-type) alleles were used as the ref-
erences. Genetic analysis showed a significant association
between endometriosis and genetic variation at the SNP
site of rs10953316 with a lower frequency of the A allele
in patients than in controls (p = 0.008; OR = 0.53; 95 % CI:
0.36-0.79) (Table 1). Genotype analysis of the rs10953316
site supported the protective potential of the AG genotype
in endometriosis development compared with the refer-
ence GG genotype (OR = 0.45; 95 % CI: 0.29-0.7). The
AA genotype was not found to show a dominant effect
due to the limited sample size. Allelic and genotype
analyses of the other SNPs showed no statistically sig-
nificant differences.
MUC17 polymorphisms and infertility
Because endometriosis is considered one of the factors
that cause infertility, we next studied the relationship be-
tween MUC17 SNPs and infertility. The endometriosis
patients were sub-grouped into the fertile and infertile
groups for allele distribution analysis. The results shown
in Table 2 indicate that the genetic variant rs4729655
is a protective genetic factor for infertility in patients
(p = 0.0465; OR = 0.42; 95 % CI: 0.21-0.82). The genetic
variant at rs4729656 also showed a protective ten-
dency, although this result did not reach statistical sig-
nificance after Bonferroni correction.
Fig. 1 Locations of the selected SNPs and their linkage disequilibrium association in the MUC17 gene in Taiwanese endometriosis patients. (a) Genetic
alterations of rs4729645, rs10953316 and rs74974199 are located in the coding sequence region, while those of rs4729655 and rs4729656 are located at
the 3′ end of the untranslated region in MUC17. (b) Values are shown with Lewontin’s D’
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MUC17 polymorphism and CA125 levels
Cancer antigen 125 (CA125), also known as MUC16, is a
commonly used serum biomarker to monitor the progress
and recurrence of ovarian malignancy and benign condi-
tions, including endometriosis. It has been shown that
serum CA125 levels are markedly elevated in women with
cystic ovarian endometriosis and/or deeply infiltrating
endometriosis compared with women in the luteal phase
with minimal or mild endometriosis [26]. Therefore, we
asked whether SNPs in MUC17 can affect the serum
CA125 levels in patients. Patients were sub-grouped into
two groups for genetic analyses based on the CA125 level:
Table 1 Genotype and allele distributions of SNPs in MUC17 gene in Taiwanese endometriosis patients and controls
Genotype/allele No. (%) of patients No. (%) of controls P-valuea Corrected P-valueb OR 95 % CI
rs4729645 TT 0 (0.0) 2 (1.0) 0.13 0.65 0.00 NA
CT 61 (33.0) 76 (39.8) 0.73 0.48-1.12
CC 124 (67.0) 113 (59.2) 1.00
T 61 (16.5) 80 (20.9) 0.12 0.6 0.71 0.47-1.09
C 309 (83.5) 302 (79.1) 1.00
rs10953316 AA 1 (0.5) 1 (0.5) 0.0018* 0.009* 0.77 0.05-12.65
AG 45 (23.8) 77 (40.5) 0.45 0.29-0.70
GG 143 (75.7) 112 (58.9) 1.00
A 47 (12.3) 79 (20.8) 0.0016* 0.008* 0.53 0.36-0.79
G 335 (87.7) 301 (79.2) 1.00
rs74974199 CC 3 (1.6) 1 (0.5) 0.24 1.2 2.86 0.29-28.61
CG 36 (19.4) 48 (25.4) 0.71 0.44-1.17
GG 14 7 (79.0) 140 (74.1) 1.00
C 42 (11.3) 50 (13.2) 0.42 2.1 0.83 0.54-1.29
G 330 (88.7) 328 (86.8) 1.00
rs4729655 TT 27 (14.6) 21 (11.1) 0.58 2.90 1.35 0.71-2.54
CT 96 (51.9) 104 (54.7) 0.97 0.62-1.51
CC 62 (33.5) 65 (34.2) 1.00
T 150 (40.5) 146 (38.4) 0.55 2.75 1.09 0.82-1.46
C 220 (59.5) 234 (61.6) 1.00
rs4729656 TT 21 (11.3) 19 (10.0) 0.90 4.5 1.17 0.59-2.34
AT 82 (44.1) 83 (43.7) 1.05 0.68-1.61
AA 83 (44.6) 88 (46.3) 1.00
T 124 (33.3) 121 (31.8) 0.66 3.3 1.07 0.79-1.45
A 248 (66.7) 259 (68.2) 1.00
*Indicates statistical significance
aP-values were calculated using χ2 test
bP-values were corrected by Bonferroni correction
Table 2 Allele distributions of SNPs in MUC17 gene vs. infertility
Polymorphism Infertile Non-Infertile P-valuea Corrected
P-valueb
OR 95 % CI
MAF MAF
rs4729645 23.1 13.8 0.090 0.45 1.83 0.87-3.82
rs10953316 9.6 12.2 0.60 3.0 0.84 0.46-1.53
rs74974199 13.5 11.4 0.68 3.40 1.20 0.49-2.90
rs4729655 25.0 44.5 0.0093* 0.0465* 0.42 0.21-0.82
rs4729656 21.2 35.4 0.046* 0.23 0.48 0.24-0.98
*Indicates statistical significance
MAF: minor allele frequency
aP-values were calculated using χ2 test
bP-values were corrected by Bonferroni correction
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high CA125 (≥35 KU/L) and low CA125 (<35 KU/L)
groups [27, 28]. Our data indicated that patients with the
rs4729655 SNP showed a significantly high expression level
of CA125 (p = 0.038; OR = 0.48; 95 % CI: 0.28-0.83). Gen-
etic variation at rs74974199 also showed a correlation with
elevated CA125 expression levels; however, such correlation
did not reach statistical significance after Bonferroni correc-
tion. By contrast, patients with genetic variation at rs4729656
showed a tendency toward a lower CA125 level (Table 3).
MUC17 rs10953316 polymorphism controls its protein
expression level
Based on above findings, the rs10953316 polymorphism
was defined as a unique genetic factor regulating
endometriosis development. However, this SNP is a si-
lent genetic variation resulting in no amino acid change
(Thr2355Thr). Therefore, we asked whether such a SNP
can induce an RNA structural conformational change
using the MaxExpect algorithm from the RNAstructure
web server [25]. MaxExpect analysis revealed that the
mRNA with genetic variation at rs10953316 forms an
additional loop adjacent to the SNP site (Fig. 2a). Be-
cause mRNA structural change could be a hindrance to
its stability and translation efficiency [29], we performed
immunohistochemistry on endometriosis tissues to see
whether such variation can influence the total amount of
MUC17. As shown in Fig. 2B, patients with AA geno-
type at rs10953316 showed low MUC17 levels in their
Table 3 Allele distributions of SNPs in MUC17 gene vs. CA-125 level
Polymorphism CA125≥ 35c CA125 < 35 P-valuea Corrected
P-valueb
OR 95 % CI
MAF MAF
rs4729645 15.1 13.6 0.76 3.80 1.12 0.61-2.13
rs10953316 13.0 12.5 0.91 4.55 1.03 0.42-2.51
rs74974199 14.4 5.7 0.045* 0.225 2.75 0.99-7.61
rs4729655 64.4 46.6 0.0076* 0.038* 2.08 1.20-3.57
rs4729656 28.8 44.3 0.015* 0.075 0.49 0.28-0.87
*Indicates statistical significance
MAF: minor allele frequency
aP-values were calculated using χ2 test
bP-values were corrected by Bonferroni correction
cCA125 level: KU/L
Fig. 2 Influence of rs10953316 SNP on MUC17 mRNA structure and protein expression. (a) Partial mRNA structure of wild-type and
rs10953316 SNP in MUC17 were predicted by MaxExpect. Symbol *indicates the reference allele G and minor allele A sites of the rs10953316 SNP.
(b) Immunohistochemistry against MUC17 was performed on endometrial tissues in patients. Representative staining results in patients with GG (left),
AG (middle), and AA (right) genotypes at rs10953316 SNP site are shown. Specific staining can be detected at the edges of endometrium (arrows)
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endometrium, patients with GA genotype showed moder-
ate levels, and strong staining could be found in patients
with GG genotype.
Discussion
In this study, we showed molecular evidence that the A
allele of rs10953316 in MUC17 may function as a pro-
tective factor in endometriosis development. One of our
limitations is the relatively small sample size, so that
genotype AA at rs10953316 did not show a stronger ef-
fect (OR = 0.77, 95 % CI: 0.05-12.65) than the genotype
AG (OR = 0.45; 95 % CI: 0.29-0.7). Although the
rs10953316 polymorphism is a silent genetic variation,
the total protein amount of MUC17 can be influenced
probably due to RNA structural conformational change
(Fig. 2). Our finding supports the previous hypothesis
that structural change in RNA coding region can lead to
ribosome pause and affect translational efficiency [29].
Similar finding was also evidenced by Nackley et al. that
haplotypes divergent in synonymous changes in human
COMT gene alter the mRNA structure with additional
loops and reduced the amount of translated protein,
which subsequently affected its function such as pain
perception [30]. Because the extracellular domain of
MUC17 protein contains several EGF-like functional do-
mains, reduction of MUC17 expression by rs10953316
SNP may down-regulate the erbB signaling leading to in-
hibition of cell proliferation [23]. In addition, SEA do-
main at the C-terminal region of MUC17 is critical for
its autoproteolysis, which controls cell migration and in-
vasion [31]. These studies provide clues for us to pre-
sume that rs10953316 SNP plays a protective role in
endometriosis development by reducing total MUC17
expression and the downstream signaling, whereas the
detailed mechanism remains to be further investigated.
Another SNP, rs4729655, was linked to endometriosis-
related infertility and was associated with abnormally
high levels of CA125. The rs4729655 SNP site is located
at the 3′-UTR of MUC17, a regulatory region for mRNA
stability and miRNA binding. We next analyzed whether
there was any possible miRNA targets gained or lost due
to genetic variation at the rs4729655 SNP site. Our study
found that genetic variation at rs4729655 resulted in the
gain of miR-4508 and loss of miR-3158-3p toward the
3′-UTR of MUC17; thus, this SNP site may be involved
in multiple miRNA interactions and gene regulation.
Our previous study showed that a miR-125b binding site
variation at the 3′-UTR of BMPR1B defines endometri-
osis susceptibility and CA125 levels [32]. Currently, bio-
functions and downstream targets of miR-4508 and
miR-3158-3p are still largely unknown. However, studies
on the miRNAome of different cancer types using a deep
sequencing approach provided solid evidence indicating
the involvement of these two miRNAs in cancer
development [33–36]. Particularly, miR-3158-3p expres-
sion was found to be associated with disease states in
the female reproductive tract, including ovarian cancer
and endometriosis [35]. Whether dysregulation of these
two miRNAs could lead to infertility remains unclear.
Further studies on these two miRNAs may provide in-
sights to uncover the detailed mechanisms regarding
how they regulate the development of female reproduct-
ive diseases.
One obstacle of this study was that the SNP associated
with endometriosis development did not show an influ-
ence on infertility or CA125 levels in patients, and vice
versa. Our data may reflect that more than 50 % of pa-
tients with endometriosis-related infertility are diag-
nosed as having minimal or mild clinical symptoms [37].
By contrast, the sensitivity and specificity of the CA125
blood test was also found to be limited, not necessary
correlating with clinical stages. Therefore, it was recom-
mended as an indication that women with high CA125
levels should receive further diagnostic screening and
treatment [38, 39]. Cytokine/hormone networking, good
oocyte quality and the success of embryo implantation
may be the key players to determine endometriosis-
related infertility. Because mucins have been found to
play roles in regulating the immune responses of the re-
productive tract and cellular proliferation of endometrial
cells, whether MUC17 also plays such a roles is an inter-
esting topic for us to further investigate.
Conclusions
In this study, we analyzed and found the association
between MUC17 polymorphisms and endometriosis,
endometriosis-related infertility and CA125 in a Taiwanese
population. However, the relatively small sample size is
one limitation of this study, and the conclusions should be
further validated by another study cohort. The detailed
regulatory mechanisms regarding how MUC17 functions
and collaborates with its binding miRNAs in promoting
endometriosis development remain to be elucidated.
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